Yoonjin Cho

发表

therapy for previously treated indolent non-Hodgkin lymphoma , as δ Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-

R. Ulrich, J. Byrd, J. Leonard, 2014 .

Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis

J. Oh, S. Suh, Yun-Kyoung Song, 2022, Targeted Oncology.

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

J. Byrd, I. Flinn, Jennifer R. Brown, 2014, Blood.

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A. Zelenetz, I. Flinn, T. Kipps, 2014 .

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Yoonjin Cho, John P Leonard, R. Ulrich, 2014, Blood.

Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.

A. Zelenetz, M. Keating, S. O'brien, 2015 .

A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A. Zelenetz, I. Flinn, T. Kipps, 2014 .

Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).

Jeffrey A Jones, I. Flinn, Jennifer R. Brown, 2015 .

RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Jeffrey A Jones, F. Bosch, P. Feugier, 2015 .

Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

Inhibitory activity of Aralia continentalis roots on protein tyrosine phosphatase 1B and rat lens aldose reductase

S. Kang, H. Jung, Jae-Sue Choi, 2012, Archives of Pharmacal Research.

Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition containing L-aspartic acid in patients with acute lymphoblastic leukemia

J. Oh, In-Wha Kim, Sung-Soo Yoon, 2023, Frontiers in Nutrition.

Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots

Sanghyuk Lee, J. Choi, B. Min, 2013, Archives of pharmacal research.

Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots

Sanghyuk Lee, B. Min, H. Jung, 2013, Archives of pharmacal research.